scholarly journals New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions

2020 ◽  
Vol 11 ◽  
Author(s):  
Nathaniel Edward Bennett Saidu ◽  
Chiara Bonini ◽  
Anne Dickinson ◽  
Magdalena Grce ◽  
Marit Inngjerdingen ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Current Status ◽  
Future Directions ◽  
Host Disease ◽  
Graft Versus Host ◽  
New Approaches

scholarly journals New approaches for preventing and treating chronic graft-versus-host disease

Blood ◽  
2005 ◽  
Vol 105 (11) ◽  
pp. 4200-4206 ◽  
Author(s):  
Stephanie J. Lee
Keyword(s):  
Graft Versus Host Disease ◽  
Older Patients ◽  
Chronic Gvhd ◽  
Hematopoietic Stem ◽  
Host Disease ◽  
Graft Versus Host ◽  
New Approaches ◽  
Blood Transplantation ◽  
Substantial Problem ◽  
Related Mortality

Abstract Despite improvements in the practice of allogeneic hematopoietic stem cell transplantation (HCT) over the last 25 years, chronic graft-versus-host disease (GVHD) remains a substantial problem with little change in the incidence, morbidity, and mortality of this complication. In fact, with increased use of peripheral blood, transplantation of older patients, and less immediate transplantation-related mortality, the prevalence of chronic GVHD may increase. One of the difficulties in combating chronic GVHD is a lack of understanding about the pathophysiology of the syndrome. Inherent difficulties in conducting human clinical trials also contribute to the lack of meaningful progress. This review covers potential new approaches to the prevention and treatment of chronic GVHD.

scholarly journals Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges

2021 ◽  
Vol 22 (18) ◽  
pp. 9676
Author(s):  
Mehrdad Hefazi ◽  
Sara Bolivar-Wagers ◽  
Bruce R. Blazar
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Graft Versus Host Disease ◽  
Immune Homeostasis ◽  
Clinical Safety ◽  
Future Directions ◽  
T Cell Therapy ◽  
Hematopoietic Stem ◽  
Host Disease ◽  
Graft Versus Host

Graft-versus-host disease (GVHD) is the leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Immunomodulation using regulatory T cells (Tregs) offers an exciting option to prevent and/or treat GVHD as these cells naturally function to maintain immune homeostasis, can induce tolerance following HSCT, and have a tissue reparative function. Studies to date have established a clinical safety profile for polyclonal Tregs. Functional enhancement through genetic engineering offers the possibility of improved potency, specificity, and persistence. In this review, we provide the most up to date preclinical and clinical data on Treg cell therapy with a particular focus on GVHD. We discuss the different Treg subtypes and highlight the pharmacological and genetic approaches under investigation to enhance the application of Tregs in allo-HSCT. Lastly, we discuss the remaining challenges for optimal clinical translation and provide insights as to future directions of the field.

Sign in / Sign up

Export Citation Format

Share Document